VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for large disease areas of high unmet medical need.

By combining state-of-the-art technologies and novel and scientific concepts, VectorY’s mission is to bring innovative therapies to patients worldwide.

Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases.

With R&D and manufacturing facilities in Amsterdam, VectorY develops proprietary & partnered programs based on its novel AAV-based vectorized antibody & gene therapy platform. Product candidates are based on new vector technologies, which will enable the next generation of highly scalable manufacturing processes within VectorY’s own manufacturing facilities. Our manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands, with the capability to deliver suspension based AAV viral vector manufacturing of up to 2000L for both clinical and commercial supply.

Benhamou Global Ventures

Eli Lilly & Company Foundation

Forbion Capital Partners

VectorY

Next to the great news about the $138 million raise for VectorY, we also have other news! 

VectorY welcomes Joachim Witjens in his new role as junior finance specialist. 

Glad to have you in our team Joachim. Good luck! 

#VectorY #genetherapy #newemployee #VectorYan #ALS #Biotech #innovation #neurodegenerativediseases

Today, we announced the raise of €129 Million ($138 Million) in a series A financing round which will be instrumental in supporting the clinical development of VTx-002, targeting TDP-43 for the treatment of ALS.
 
We will also be using the proceeds to accelerate development of the vectorized antibody platform and additional pipeline programs targeting proteinopathies that cause other neurodegenerative diseases.
 
The round was one of the largest private biotech financings in Europe in 2023.
 
Our CEO, Sander van Deventer, commented:
“The Series A financing, supported by such a strong syndicate of European and US investors, is an endorsement of our pioneering approach, world-class team and commitment to bring much-needed therapies to patients with
neurodegenerative diseases.”
 
#VectorY #GeneTherapy #neurodegeneration #biotechnology #financing #LifeSciences #biotech #innovation
 
Read the full news update: https://lnkd.in/ee2mEYxQ

Last week our new DSP scientist Mariana São Pedro started at VectorY.

We are delighted to welcome her as a new VectorYan.

Good luck Mariana!

A very warm welcome to our new intern and VectorYan Daan van den Burg. 

Good luck Daan!

#VectorY #internship #graduates

VectorY is hiring!

Check out our USP scientist vacancy and join our dynamic team of scientists, technicians and other professionals who are focused on developing the best vectorized antibody treatments for patients.

https://lnkd.in/e65UeUYp

A great opportunity for a Technology Transfer Specialist who is going to support the process transfer activities from VectorY R&D to an external GMP manufacturing facility as well as overseeing the GMP operations.

Check out: https://lnkd.in/ew-kNuii

#VectorY #technologytransfer #vacancy #genetherapy #biotech #Amsterdam #GMP #technologytransferspecialist

Great opportunity for an USP Scientist!
This is your chance to join VectorY in our mission to bring innovation therapies to patients worldwide!

https://lnkd.in/e65UeUYp

#USP #Scientist #VectorY #ProcessDevelopment #vacancy #Amsterdam #SciencePark #PhD #career #PDteam

Today we are very pleased to welcome our new scientist Vectorized Antibody Therapy; Alessandro Moro. 

Great to have you in our team Alessandro!

We are looking for an Bioanalytical Laboratory Technician: great chance to be part of our journey!

https://lnkd.in/ek3mvu75

#technician #VectorY #genetherapy #biotech #assay #assaydevelopment
#career #vacancy #opportunity #ALS #assayexecution

They did it!

Last weekend these sportive VectorYans run the ‘Dam to Dam loop’.  We are proud!

Ross Patterson 
Linda Borst 
Jelmer Willems 
Margreet van Beek

VectorY is a biotech company that develops vectorized antibody treatments for neurodegenerative diseases, aiming to enable longer, better lives.

COM:VECTORYTX

VectorY

Filings Not Available